International Journal of Biotech
Trends and Technology

Research Article | Open Access | Download PDF
Volume 13 | Issue 1 | Year 2023 | Article Id. IJBTT-V13I1P602 | DOI : https://doi.org/10.14445/22490183/IJBTT-V13I1P602

Synergistic Role of Renin-Angiotensin System and Dyslipidemia in Diabetic Kidney Disease: A Mini Review

Umme Najiya Mahwish, Swetha Ch, Babi Heera, K. Rudrama Devi, Sree Bhushan Raju, Parveen Jahan

Received Revised Accepted Published
12 Feb 2023 16 Mar 2023 29 Mar 2023 10 Apr 2023

Citation :

Umme Najiya Mahwish, Swetha Ch, Babi Heera, K. Rudrama Devi, Sree Bhushan Raju, Parveen Jahan, "Synergistic Role of Renin-Angiotensin System and Dyslipidemia in Diabetic Kidney Disease: A Mini Review," International Journal of Computer Trends and Technology (IJCTT), vol. 13, no. 1, pp. 7-15, 2023. Crossref, https://doi.org/10.14445/22490183/IJBTT-V13I1P602

Abstract

Renin-angiotensin system (RAS) is a well-documented active mediator in progressive diabetic kidney disease (DKD). Ancillary to hyperglycemia association with dyslipidemia appears to impact the initiation and progression of renal injury in diabetes, giving a link between plasma lipoproteins and angiotensin II in the causation of renal injury under a hyperglycemic setup. Activation of local RAS convoluted in hyperlipidemia-mediated renal injury results in the extracellular matrix deposition in the tubular interstitium, suggesting that the major effector peptide (Ang II) of the RAS pathway and lipoproteins does not act independently but acts synergistically facilitating the progression of chronic kidney disease. Appreciating the relationship between Angiotensin Converting Enzyme (ACE) Insertion/Deletion (I/D) genotypes or any other ACE gene polymorphism and dyslipidemia with DKD opens up the scope for early recognition of diabetic patients with a high risk of DKD. Systematic in-depth observational and ethnic population studies considering ACE Inhibitors and anti-lipid drugs in relation to ACE genotypes are warranted to help understand the role of the ACE gene that appears to be a major contributor to the complex mechanism involved and the environment in the form of lifestyle in diabetic kidney disease complication.

Keywords

Renin-angiotensin system, Diabetic kidney disease, Hyperglycemia, Dyslipidemia, ACE gene polymorphism.

References

[1] Radica Z Alicic, Michele T Rooney, and Katherine R Tuttle, “Diabetic Kidney Disease: Challenges, Progress, and Possibilities,” Clinical Journal of the American Society of Nephrology, vol. 12, no. 12, pp. 2032–2045, 2017.
[CrossRef] [Google Scholar] [Publisher Link]

[2] Sarah Wild et al., “Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030,” Diabetes care, vol. 27, no. 5, pp. 1047–1053, 2004.
[CrossRef] [Google Scholar] [Publisher Link]

[3] Andy KH Lim, “Diabetic Nephropathy - Complications and Treatment,” International Journal of Nephrology and Renovascular Disease, vol. 7, pp. 361–381, 2014.
[CrossRef] [Google Scholar] [Publisher Link]

[4] Mahwish Umme Najiya et al., “Link between ACE I/D Gene Polymorphism and Dyslipidemia in Diabetic Nephropathy: A Case-control Study from Hyderabad, India,” Indian Journal of Nephrology, vol. 30, no. 2, pp. 77–84, 2020.
[CrossRef] [Google Scholar] [Publisher Link]

[5] Tanuj Chawla, Deepika Sharma, and Archana Singh, “Role of the Renin Angiotensin System in Diabetic Nephropathy,” World Journal of Diabetes, vol. 1, no. 5, pp. 141–145, 2010.
[CrossRef] [Google Scholar] [Publisher Link]

[6] Gijs H Goossens, “The Renin-Angiotensin System in the Pathophysiology of Type 2 Diabetes,” Obesity Facts, vol. 5, no. 4, pp. 611– 624, 2012.
[CrossRef] [Google Scholar] [Publisher Link]

[7] Zohreh Rahimi, Mahmoudreza Moradi, and Hamid Nasri, “A Systematic Review of the Role of Renin Angiotensin Aldosterone System Genes in Diabetes Mellitus, Diabetic Retinopathy and Diabetic Neuropathy,” Journal of Research in Medical Sciences, vol. 19, no. 11, pp. 1090–1098. 2014.
[Google Scholar] [Publisher Link]

[8] Ming-Sheng Zhou, and Ivonne Hernandez Schulman, “Prevention of Diabetes in Hypertensive Patients: Results and Implications from the VALUE trial,” Vascular Health and Risk Management, vol. 5, no. 1, pp. 361–368, 2009.
[CrossRef] [Google Scholar] [Publisher Link]

[9] James Matthew Luther, and Nancy J. Brown, “The Renin-Angiotensin-Aldosterone System and Glucose Homeostasis,” Trends in pharmacological sciences, vol. 32, no. 12, pp. 734–739, 2011.
[CrossRef] [Google Scholar] [Publisher Link]

[10] Patricia C. Underwood, and Gail K. Adler, “The Renin Angiotensin Aldosterone System and Insulin Resistance in Humans,” Current hypertension reports, vol. 15, no. 1, pp. 59–70, 2013.
[CrossRef] [Google Scholar] [Publisher Link]

[11] Susan B. Gurley, and Thomas M. Coffman, “The Renin-Angiotensin System and Diabetic Nephropathy,” Seminars in Nephrology, vol. 27, no. 2, pp. 144–152, 2007.
[CrossRef] [Google Scholar] [Publisher Link]

[12] R. Zatz et al., “Prevention of Diabetic Glomerulopathy by Pharmacological Amelioration of Glomerular Capillary Hypertension,” Journal of Clinical Investigation, vol. 77, no. 6, pp. 1925–1930, 1986.
[CrossRef] [Google Scholar] [Publisher Link]

[13] G. H. Tesch, “MCP-1/CCL2: a New Diagnostic Marker and Therapeutic Target for Progressive Renal Injury in Diabetic Nephropathy,” American Journal of Physiology-Renal Physiology, vol. 294, no. 4, pp. F697–F701, 2008.
[CrossRef] [Google Scholar] [Publisher Link]

[14] Takashi Wada et al., “Monocyte Chemoattractant Protein-1: Does it play a Role in Diabetic Nephropathy?,” Nephrology Dialysis Transplantation, vol. 18, pp. 457-459, 2003.
[CrossRef] [Google Scholar] [Publisher Link]

[15] A. Zhernakova et al., “Genetic Variants of RANTES are Associated with Serum RANTES Level and Protection for Type 1 Diabetes,” Genes and Immunity, vol. 7, pp. 544-54, 2006.
[CrossRef] [Google Scholar] [Publisher Link]

[16] Bernardo Rodríguez-Iturbe et al., “Role of Immunocompetent Cells in Nonimmune Renal Diseases,” Kidney International, vol. 59, no. 5, pp. 1626-1640, 2001.
[CrossRef] [Google Scholar] [Publisher Link]

[17] Tanuj Chawla, Deepika Sharma, and Archana Singh, “Role of the Renin Angiotensin System In Diabetic Nephropathy,” World journal of diabetes, vol. 1, no. 5, pp. 141-145, 2010.
[CrossRef] [Google Scholar] [Publisher Link]

[18] Sergio Mezzano et al., “Renin-angiotensin System Activation and Interstitial Inflammation in Human Diabetic Nephropathy,” Kidney International, vol. 64, pp. S64-S70, 2003.
[CrossRef] [Google Scholar] [Publisher Link]

[19] Kamal Dwebeh, Abdullah Cheikh Ibrahim, and Maher Madi, “Left Ventricular Dysfunction in Patients with Liver Disease," SSRG International Journal of Medical Science, vol. 8, no. 10, pp. 1-5, 2021.
[CrossRef] [Publisher Link]

[20] Szu-chi Chen, and Chin-Hsiao Tseng, “Dyslipidemia, Kidney Disease, and Cardiovascular Disease in Diabetic Patients,” The Review of Diabetic Studies, vol. 10, no. 2-3, pp. 88–100, 2013.
[CrossRef] [Google Scholar] [Publisher Link]

[21] Daiji Kawanami, Keiichiro Matoba, and Kazunori Utsunomiya, “Dyslipidemia in Diabetic Nephropathy,” Renal Replacement Therapy, vol. 2, no. 16, 2016.
[CrossRef] [Google Scholar] [Publisher Link]

[22] Milagros J. Jacobs et al., “Prevalence and Control of Dyslipidemia among Persons with Diabetes in the United States,” Diabetes Research and Clinical Practice, vol. 70, no. 3, pp. 263–269, 2005.
[CrossRef] [Google Scholar] [Publisher Link]

[23] Bishwajit Bhowmik et al., “Serum Lipid Profile and Its Association with Diabetes and Prediabetes in a Rural Bangladeshi Population,” International Journal of Environmental Research and Public Health, vol. 15, no. 9, pp. 1944, 2018.
[CrossRef] [Google Scholar] [Publisher Link]

[24] N.D. Vaziri, K. Liang, and J.S. Parks, “Acquired Lecithin-Cholesterol Acyltransferase Deficiency in Nephrotic Syndrome,” American Journal of Physiology-Renal Physiology, vol. 280, no. 5, pp. F823–F828, 2001.
[CrossRef] [Google Scholar] [Publisher Link]

[25] Nosratola D. Vaziri, Tadashi Sato, and Kaihui Liang, “Molecular Mechanisms of Altered Cholesterol Metabolism in Rats with Spontaneous Focal Glomerulosclerosis,” Kidney International, vol. 63, no. 5, pp. 1756–1763, 2003.
[CrossRef] [Google Scholar] [Publisher Link]

[26] Hartmut Scheuer et al., “Oxidative Stress in Hyperlipidemia- Induced Renal Damage,” American Journal of Physiology-Renal Physiology, vol. 278, pp. F63-F74, 2000.
[CrossRef] [Google Scholar] [Publisher Link]

[27] Sho-ichi Yamagishi, and Takanori Matsui, “Advanced Glycation end Products, Oxidative Stress and Diabetic Nephropathy,” Oxidative Medical and Cellular Longevity, vol. 3, vo. 2, pp. 101–108, 2010.
[CrossRef] [Google Scholar] [Publisher Link]

[28] Bertram L. Kasiske et al., “The Renal Injury of Diet-Induced Hypercholesterolemia in Rats,” Kidney International, vol. 37, no. 3, pp. 880–891, 1990.
[CrossRef] [Google Scholar] [Publisher Link]

[29] Michal Herman-Edelstein et al., “Altered Renal Lipid Metabolism and Renal Lipid Accumulation in Human Diabetic Nephropathy,” Patient-Oriented and Epidemiological Research, vol. 55, no. 3, pp. 561–572, 2014.
[CrossRef] [Google Scholar] [Publisher Link]

[30] M. C. Bulbul et al., “Disorders of Lipid Metabolism in Chronic Kidney Disease,” Blood Purification, vol. 46, no. 2, pp. 144–152, 2018.
[CrossRef] [Google Scholar] [Publisher Link]

[31] Aleix Cases, and Elisabet Coll, “Dyslipidemia and the Progression of Renal Disease in Chronic Renal Failure Patients,” Kidney International, vol. 68, pp. S87–S93, 2005.
[CrossRef] [Google Scholar] [Publisher Link]

[32] J. F. Moorhead et al., “Lipid Nephrotoxicity in Chronic Progressive Glomerular and Tubulo-Interstitial Disease,” The Lancet, vol. 320, no. 8311, pp. 1309–1311, 1982.
[CrossRef] [Google Scholar] [Publisher Link]

[33] Roberto Trevisan, Alessandro R Dodesini, and Giuseppe Lepore, “Lipids and Renal Disease,” Journal of the American Society of Nephrology, vol. 17, no.4, pp. S145–S147, 2006.
 [CrossRef] [Google Scholar] [Publisher Link]

[34] Mordchai Ravid, Lily Neumann, and Michael Lishner, “Plasma Lipids and the Progression of Nephropathy in Diabetes Mellitus Type 2: Effect of ACE Inhibitors,” Kidney International, vol. 47, no. 3, pp. 907–910, 1995.
[CrossRef] [Google Scholar] [Publisher Link]

[35] N. Tolonen et al., “Relationship between Lipid Profiles and Kidney Function in Patients with Type 1 Diabetes,” Diabetologia, vol. 51, no. 1, pp. 12–20, 2008.
[CrossRef] [Google Scholar] [Publisher Link]

[36] M. Kajingulu, Francois et al, “Albuminuria Status and Patterns of Dyslipidemia among Type 2 Diabetes Black Patients Managed at a Tertiary Health-care Hospital: A Post hoc Analysis,” Saudi Journal of Kidney Diseases and Transplantatio, vol. 29, no. 3, pp. 649- 657, 2018.
[CrossRef] [Google Scholar] [Publisher Link]

[37] Lu Chun-Feng et al, “Comparisons of the Relationships between Multiple Lipid Indices and Diabetic Kidney Disease in Patients with Type 2 Diabetes: A Cross-Sectional Study,” Frontiers in Endocrinology, vol. 13, 2022.
[CrossRef] [Google Scholar] [Publisher Link]

[38] Meteb Altaf et al., "Monitoring Diabetic Foot by Designing a New Smart Sole,” SSRG International Journal of Pharmacy and Biomedical Engineering, vol. 7, no. 3, pp. 15-20, 2020.
[CrossRef] [Publisher Link]

[39] Ni Jie et al, “Activation of Renin-Angiotensin System is Involved in Dyslipidemia-Mediated Renal Injuries in Apolipoprotein E knockout mice and HK-2 cells,” Lipids in Health and Disease, vol. 12, no. 49, 2013.
[CrossRef] [Google Scholar]  [Publisher Link]

[40] Bhaskar VKS Lakkakula et al., “Genetic Association of ACE gene I/D Polymorphism with the Risk of Diabetic Kidney Disease; a Meta-Analysis,” Journal of Nephropathology, vol. 8, no. 4, 2019.
[CrossRef] [Google Scholar] [Publisher Link]

[41] Chin-Hsiao Tseng, Ching-Ping Tseng, and Choon-Khim, “Chong Joint Effects of Hypertension, Smoking, Dyslipidemia and Obesity and Angiotensin-Converting Enzyme DD Genotype on Albuminuria in Taiwanese Patients with Type 2 Diabetes Mellitus,” Clinical Biochemistry, vol. 43, no. 7-8, pp. 629-634, 2010.
[CrossRef] [Google Scholar] [Publisher Link]

[42] D.K. Nagi et al., “Angiotensin-1-Converting Enzyme (ACE) Gene Polymorphism, Plasma ACE levels, and their Association with the Metabolic Syndrome and Electrocardiographic Coronary Artery Disease in Pima Indian,” Metabolism, vol. 47, no. 5, pp. 622-626, 1998.
[CrossRef] [Google Scholar] [Publisher Link]

[43] Zohreh Rahimi, “ACE insertion/deletion (I/D) Polymorphism and Diabetic Nephropathy,” Journal of Nephropathology, vol. 1, no. 3, pp. 143-151, 2012.
[CrossRef] [Google Scholar] [Publisher Link]

[44] Hans-Henrik Parving et al., “Effect of Deletion Polymorphism of Angiotensin Converting Enzyme Gene on Progression of Diabetic Nephropathy during Inhibition of Angiotensin Converting Enzyme: Observational Follow up Study,” BMJ, vol. 313, pp. 591–594, 1996.
[CrossRef] [Google Scholar] [Publisher Link]

[45] G. Penno et al, “Effect of Angiotensin-Converting Enzyme (ACE) Gene Polymorphism on Progression of Renal Disease and the Influence of ACE inhibition in IDDM Patients: Findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM,” Diabetes, vol. 47, no. 9, pp. 1507–1511, 1998.
[CrossRef] [Google Scholar] [Publisher Link]

[46] Jacobsen Peter et al., “Genetic Variation in the Renin-Angiotensin System and Progression of Diabetic Nephropathy,” Journal of the American Society of Nephrology, vol. 14, no. 11, pp. 2843–2850, 2003.
[CrossRef] [Google Scholar] [Publisher Link]

[47] Steen Andersen et al, “Renoprotective Effects of Losartan in Diabetic Nephropathy: Interaction with ACE Insertion/Deletion Genotype?,” Kidney International, vol. 62, pp. 192–198, 2002.
[CrossRef] [Google Scholar] [Publisher Link]

[48] Steen Andersen et al, “Long-term Renoprotective Effects of Losartan in Diabetic Nephropathy: Interaction with ACE Insertion/Deletion Genotype?,” Diabetologia Praktyczna, vol, 4, no. 3, pp. 211-218, 2003.
[Google Scholar] [Publisher Link]

[49] Sung Kyu Ha et al, “ACE DD Genotype is more Susceptible than ACE II and ID Genotypes to the Antiproteinuric effect of ACE Inhibitors in Patients with Proteinuric Non-Insulin-Dependent Diabetes Mellitus,” Nephrology Dialysis Transplantation, vol. 15, no. 10, pp. 1617–1623, 2000.
[CrossRef] [Google Scholar] [Publisher Link]

[50] Masakazu Haneda et al., “Antiproteinuric Effect of Candesartan Cilexetil in Japanese Subjects with Type 2 Diabetes and Nephropathy,”Diabetes Research and Clinical Practice, vol. 66, no. 1, pp. 87–95, 2004.
[CrossRef][Google Scholar] [Publisher Link]

[51] W. Y. So et al., “Angiotensin-Converting Enzyme (ACE) Inhibition in type 2, Diabetic Patients - Interaction with ACE Insertion/Deletion Polymorphism,” Kidney International, vol. 69, no. 8, pp. 1438–1443, 2006.
[CrossRef] [Google Scholar] [Publisher Link]

[52] Hans-Henrik Parving et al, “ACE Gene Polymorphism and Losartan Treatment in Type 2 Diabetic Patients with Nephropathy,” Journal of the American Society of Nephrology, vol. 19, no. 4, pp. 771–779, 2008.
[CrossRef] [Google Scholar] [Publisher Link]

[53] Balneek Singh Cheema et al., “Endothelial Nitric Oxide Synthase Gene Polymorphisms and Renal Responsiveness to RAS Inhibition Therapy in type 2 Diabetic Asian Indians,” Diabetes research and clinical practice, vol. 99, no. 3, pp. 335-42, 2013.
[CrossRef] [Google Scholar] [Publisher Link]

[54] Neerja Aggarwal et al, “Role of Angiotensin Converting Enzyme and Angiotensinogen Gene Polymorphisms in Angiotensin Converting Enzyme Inhibitor-Mediated Antiproteinuric Action in Type 2 Diabetic Nephropathy Patients,” World Journal of Diabetes,” vol. 8, no. 3, pp. 112–119, 2017.
[CrossRef] [Google Scholar] [Publisher Link]

[55] Abdur Raza et al, “Association of Angiotensin Converting Enzyme Gene Polymorphism with Diabetic Nephropathy in Patients Using Lisinopril,” Indian Journal of Pharmacy and Pharmacology, vol. 9, no. 2, pp. 96-102, 2022.
[CrossRef] [Google Scholar] [Publisher Link]

[56] Carla Zoja et al, “Adding a Statin to a Combination of ACE Inhibitor and ARB Normalizes Proteinuria in Experimental Diabetes, which Translates into full Renoprotection,” American Journal of Physiology-Renal Physiology, vol. 299, no. 5, pp. F1203–F1211, 2010.
[CrossRef] [Google Scholar] [Publisher Link]

[57] K. F. Wellmann, and B.W. Volk, “Renal Changes in Experimental Hypercholesterolemia in Normal and in Subdiabetic Rabbits. II. Long term Studies,” Laboratory Investigation, vol. 24, no. 2, pp. 144–155, 1971.
[Google Scholar] [Publisher Link]

[58] Rey F. Rosario, and Sharma Prabhakar, “Lipids and Diabetic Nephropathy,” Current Diabetes Reports, vol. 6, pp. 455-462, 2006.
[CrossRef] [Google Scholar] [Publisher Link]